MO-I-1100_product_DataBase

Bioactivity	MO-I-1100 is an inhibitor of ASPH (Aspartyl-(Asparaginyl)-β-hydroxylase) enzymatic activity. MO-I-1100 suppresses HCC cell migration, invasion and anchorage independent growth. MO-I-1100 shows antitumor effects through inhibiting Notch signaling cascade in HCC[1].
Invitro	MO-I-1100 对细胞表面缺乏 ASPH 的 NIH3T3 细胞的活力没有影响[1]。MO-I-1100 (1-10 μM) 抑制 FOCUS 细胞的活力，该细胞具有高水平 ASPH 表达[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> MO-I-1100 相关抗体:
In Vivo	MO-I-100 (50 mg/kg，腹腔注射，每周连续 5 天，持续 2 周，然后每隔一天给药)可降低肝内原位异种移植 HCC 模型中的肿瘤生长[1]。MO-I-1100 (50 mg/kg/天，腹腔注射，持续 5 天)可降低激活的 Notch 1（裂解片段）以及下游 HES1 和 HEY1 基因表达[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:
CAS	1585217-40-8
Formula	C17H14ClNO5S
Molar Mass	379.81
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Aihara A, et al. A cell-surface β-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma. Hepatology. 2014 Oct;60(4):1302-13.

PeptideDB